Development and optimization of rutin-loaded nanolipid carrier for the healing and management of diabetic wound

This study focuses on the urgent issue of chronic wounds, especially in individuals with diabetes, where impaired tissue regeneration leads to non-healing wounds. Traditional systemic medication delivery systems sometimes fail to precisely target regions and can result in unwanted systemic side effects. Topical delivery of medication is a potential approach that aims to reduce systemic exposure, lower doses, and minimize off-target effects. However, this method faces difficulties such as medication breakdown, rapid removal, and uncontrolled discharge in chronic wounds, worsened by increasing bacterial resistance to antibiotics. Our work utilizes nanotechnology, primarily solid lipid nanoparticles (SLNs), to enhance wound healing methods due to their excellent safety record and effective encapsulation properties. Rutin is recognized for its anti-inflammatory, antioxidant, and possible antibacterial properties, making it a bioactive compound. Its proven ability to stimulate important cellular processes and promote tissue regeneration makes it an attractive option for treating diabetic wounds. Our research optimizes a lipid-based drug delivery system containing Rutin-loaded SLNs, with in vitro tests confirming the specific composition of the carrier for efficient treatment of diabetic wounds. This study represents a significant advancement in improving treatment methods for diabetic wounds by utilizing nanotechnology and Rutin-loaded SLNs to enhance and target wound healing more effectively. Further research is warranted to authenticate its clinical applicability, marking a crucial step towards enhancing diabetic wound management strategies.